Cathepsin S Inhibitors with Selective Substituent Patterns
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders involving cathepsin S, such as autoimmune disorders and chronic pain, lack effective inhibitors that specifically target cathepsin S without affecting other members of the papain superfamily, leading to potential side effects and reduced efficacy.
Innovation Solution
Development of specific compounds, including those of the formula I, which are designed to inhibit cathepsin S with improved pharmacological properties like potency, decreased cytotoxicity, and better pharmacokinetics, allowing for targeted treatment of diseases associated with aberrant cathepsin S expression or activation without substantial inhibition of other papain superfamily members.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitors are designed to target cathepsin S, then treatment efficacy for autoimmune disorders and chronic pain is improved, but selectivity against other papain superfamily members deteriorates, causing side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions (R1-R6) of the inhibitor core structure. Each substituent position is optimized to interact with specific residues in the cathepsin S active site, creating localized interactions that enhance selectivity. For example, specific bulky hydrophobic groups at P2 position create steric clashes with other papain family members while maintaining binding to cathepsin S, thus improving treatment efficacy without causing off-target side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent type (hydrophobic, hydrophilic, aromatic, aliphatic), substituent size, and electronic properties at different positions of the inhibitor scaffold. These parameter optimizations allow fine-tuning of binding affinity and selectivity. The patent demonstrates that specific parameter combinations (e.g., aromatic substituents at certain positions, specific H-bonding groups at others) dramatically improve cathepsin S selectivity while maintaining potency, thereby resolving the contradiction between efficacy and side effects.
2Reliability
If inhibitors are designed with high potency against cathepsin S, then treatment outcomes are improved, but cytotoxicity increases
Solution Approach 1:
The patent applies local quality by placing specific functional groups at strategically positioned locations on the inhibitor molecule. These localized features (such as H-bonding groups at P1 position, hydrophobic groups at P2, and charged groups at P3) create specific interaction patterns with cathepsin S that achieve high potency through cumulative weak interactions rather than strong non-specific binding. This localized optimization allows high treatment outcomes while avoiding the cytotoxicity that would result from non-specific high-affinity binding to multiple protein targets.
Solution Approach 2:
The patent uses water molecules as intermediaries in the binding interface between the inhibitor and cathepsin S. Specific design features include substituents that form water-bridged hydrogen bond networks with the enzyme. These intermediary water molecules mediate specific interactions that enhance potency while maintaining selectivity, because the water-mediated binding mode is highly dependent on the precise geometric and chemical complementarity between inhibitor and cathepsin S, thereby reducing non-specific cytotoxic effects.
3Object-affected harmful factors
If inhibitors are designed for high selectivity towards cathepsin S, then side effects are minimized, but pharmacokinetic properties deteriorate
Solution Approach 1:
The patent employs parameter changes by systematically optimizing physicochemical parameters of the inhibitor substituents to balance selectivity and pharmacokinetics. Specifically, the patent adjusts parameters such as molecular weight, logP (lipophilicity), hydrogen bond donor/acceptor counts, and polar surface area by selecting appropriate substituents. For example, the patent demonstrates that moderate lipophilicity (logP 2-4) achieved through specific hydrocarbon chain lengths and aromatic substituent choices improves membrane permeability and metabolic stability while maintaining cathepsin S selectivity, thus resolving the contradiction between minimizing side effects and achieving good pharmacokinetics.
Data Source
AI summary
Compounds of the formula (I) wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents; or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1- C6dialkylamino or; R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.